Latest & greatest articles for autism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on autism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on autism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Autism

Autism is a neurodevelopmental disorder (a type of mental disorder) characterised by difficult social interaction, impaired communication (both verbal and non-verbal), and restricted and repetitive behaviours. It forms part of the broader autism spectrum disorder (ASD), a range of similar conditions, including Asperger syndrome.

Autism is a condition that begins from early childhood and is often suspected and diagnosed by ages 1-3. It is a lifelong disability that affects how people interact with others.

Autism causes and treatment

There have been many misconceptions as to what causes autism in the past such as the MMR vaccine and diet. Extensive research and clinical trials have concluded that none of these factors cause autism or ASD. However, the real cause is little understood but research is starting to unpick potential factors such as genetics, pollution and other environmental factors. A current favoured idea is that genes inherited from a child’s parents can make them more vulnerable to developing autism, some researchers suggest that the disorder will only develop when triggered by environmental factors.

The exact cause of autism spectrum disorder is unknown, however research into the disorder suggest that it is caused by several genetic and environmental factors. Genes inherited from a child’s parents can make them more vulnerable to developing autism, some researchers suggest that the disorder will only develop when triggered by environmental factors. Read more in clinical papers on autism.

Autism can be managed with a combination of prescribed medicines and behavioural treatment, depending on the severity of the disorder. Read about clinical trials and medical advancements for the treatment of autism on Trip.

Hot topics in Trip

Users of Trip frequently look at topics around adolescents, therapies, behaviour and screening. They also explore such topics as omega-3 fatty acids, SSRIs and aripiprazole. All these topics, and more, can be easily searched for within Trip.

Top results for autism

81. Aberrant Oscillatory Synchrony Is Biased Toward Specific Frequencies and Processing Domains in the Autistic Brain Full Text available with Trip Pro

Aberrant Oscillatory Synchrony Is Biased Toward Specific Frequencies and Processing Domains in the Autistic Brain Prevailing theories suggest that autism spectrum disorder (ASD) results from impaired brain communication, causing aberrant synchrony among neuronal populations. However, it remains debated whether synchrony abnormalities are among local or long-range circuits, are circuit specific or are generalized, reflect hypersynchrony or reflect hyposynchrony, and are frequency band-specific

2016 Biological psychiatry. Cognitive neuroscience and neuroimaging

82. Assessment, diagnosis and interventions for autism spectrum disorders

. The inclusion of adults is in response to the increasing understanding that autism spectrum disorder (ASD) is a lifelong condition in which the core features of ASD persist whilst manifesting differently according to different age stages. Depending on the severity of autistic difficulties, ASD may not be evident as a presentation throughout preschool, primary, or secondary school years or in adulthood. It may not be recognised because of associated coexisting conditions. Variable environmental factors (...) on cognition. A study conducted in a gender clinic in London reported that among the 92 participants the prevalence of autistic traits, based on assessment with the Autism Spectrum Quotient (AQ) was 5.5% (3 male to female and 2 female to male transsexuals) compared to reports of clinical diagnoses of 0.5–2.0% in the general population. 49 Further indicators of possible ASD in adults are listed in Annex 2. Healthcare professionals should be aware of indicators for ASD in adults presenting with other

2016 SIGN

83. Maternal vitamin D deficiency and the risk of autism spectrum disorders: population-based study Full Text available with Trip Pro

Maternal vitamin D deficiency and the risk of autism spectrum disorders: population-based study Maternal vitamin D deficiency may increase risk of autism spectrum disorder (ASD), but direct evidence is lacking.To clarify the relationship between maternal vitamin D deficiency and offspring risk of ASD with and without intellectual disability.Using a register-based total population study (N=509 639), we calculated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) of ASD

2016 BJPsych open

84. A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder

A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder Tsiplova K, Zur RM, Ungar WJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Tsiplova K, Zur RM, Ungar WJ. A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder. Toronto, ON: Technology Assessment at SickKids (TASK). 2016 Authors' conclusions This study is the first to estimate the cost of clinical exome and genome sequencing using a bottom-up microcosting approach, The WGS using older technology (HiSeq 2500) was the most expensive test, costing almost three times as much as WES

2016 Health Technology Assessment (HTA) Database.

85. Association of Psychiatric and Neurologic Comorbidity With Mortality Among Persons With Autism Spectrum Disorder in a Danish Population Full Text available with Trip Pro

Association of Psychiatric and Neurologic Comorbidity With Mortality Among Persons With Autism Spectrum Disorder in a Danish Population Increased mortality has been reported among persons with autism spectrum disorder (ASD), especially among those who also have the comorbid condition of epilepsy or intellectual disability. The effects of psychiatric and neurologic comorbidity on mortality among persons with ASD have not been rigorously examined in large, population-based studies.To investigate

2016 EvidenceUpdates

86. Screening for Autism Spectrum Disorder in Young Children: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Autism Spectrum Disorder in Young Children: US Preventive Services Task Force Recommendation Statement. New US Preventive Services Task Force (USPSTF) recommendation on screening for autism spectrum disorder (ASD) in young children.The USPSTF reviewed the evidence on the accuracy, benefits, and potential harms of brief, formal screening instruments for ASD administered during routine primary care visits and the benefits and potential harms of early behavioral treatment for young

2016 JAMA

87. Gender Variance Among Youth with Autism Spectrum Disorders: A Retrospective Chart Review Full Text available with Trip Pro

Gender Variance Among Youth with Autism Spectrum Disorders: A Retrospective Chart Review Purpose: Increasing clinical evidence suggests an overrepresentation of gender variance (GV) among patients with autism spectrum disorders (ASDs). This retrospective chart review aims to contribute to the existing literature on co-occurring ASD and gender dysphoria (GD). We compare the rate of parent-reported GV in patients with an ASD diagnosis to that of parent-reported GV in a normative nonreferred data

2016 Transgender health

88. Cohort study: Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high

Cohort study: Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high Article Text Prognosis Cohort study Rate of epilepsy in people with autism and the rate

2016 Evidence-Based Medicine

89. A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder

A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder The Hospital for Sick Children Technology Assessment at SickKids (TASK) FULL REPORT UPDATED A MICROCOSTING AND COST-CONSEQUENCE ANALYSIS OF GENOMIC TESTING STRATEGIES IN AUTISM SPECTRUM DISORDER Authors: Kate Tsiplova, MSc Research Project Manager, Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada Richard M. Zur, PhD Research Project Manager, Child Health (...) College of Medical Genetics and Genomics ASD Autism spectrum disorder CAD Canadian dollar CMA Chromosomal microarray analysis CGES Clinical genome and exome sequencing CIHI Canadian Institute for Health Information CNV Copy number variant DD Developmental delay DSA Deterministic sensitivity analysis FISH Fluorescence in situ hybridization GE 3 LS Genomics and its ethical, economic, environmental, legal, and social aspects HTA Health technology assessment ID Intellectual disability MCA Multiple

2016 SickKids Reports

90. Diagnosing autism spectrum disorder (ASD) among adults

Diagnosing autism spectrum disorder (ASD) among adults Diagnosing autism spectrum disorder (ASD) among adults | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Diagnosing autism spectrum disorder (ASD) among adults Article Text Evidence-based case conference Diagnosing autism spectrum disorder (ASD) among adults Toshi A Furukawa Statistics from Altmetric.com Clinical case Patient: 18-year-old man Present illness : The patient

2016 Evidence-Based Mental Health

91. Autism Spectrum Disorder in Young Children: Screening

Autism Spectrum Disorder in Young Children: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Children aged 18 to 30 months The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for autism spectrum disorder (ASD) in young children for whom no concerns of ASD have been raised by their parents or a clinician. I View the Clinical Summary (...) in Population Children aged 18 to 30 months for whom no concerns of autism spectrum disorder (ASD) have been raised by their parents or a clinician Recommendation No recommendation. Grade: I (insufficient evidence) Risk Assessment Although a number of potential risk factors for ASD have been identified, there is insufficient evidence to determine if certain risk factors modify the performance characteristics of ASD screening tests, such as the age at which screening is performed or other characteristics

2016 U.S. Preventive Services Task Force

92. Air Pollution and Autism Spectrum Disorders: Causal or Confounded? Full Text available with Trip Pro

Air Pollution and Autism Spectrum Disorders: Causal or Confounded? In the last decade, several studies have examined the association between perinatal exposure to ambient air pollution and risk of autism spectrum disorder (ASD). These studies have largely been consistent, with associations seen with different aspects of air pollution, including hazardous air toxics, ozone, particulate, and traffic-related pollution. Confounding by socioeconomic status (SES) and place of residence

2015 Current environmental health reports

93. Special report: chromosomal microarray for the genetic evaluation of patients with global developmental delay, intellectual disability, and autism spectrum disorder

Special report: chromosomal microarray for the genetic evaluation of patients with global developmental delay, intellectual disability, and autism spectrum disorder Special report: chromosomal microarray for the genetic evaluation of patients with global developmental delay, intellectual disability, and autism spectrum disorder Special report: chromosomal microarray for the genetic evaluation of patients with global developmental delay, intellectual disability, and autism spectrum disorder (...) BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation BlueCross BlueShield Association. Special report: chromosomal microarray for the genetic evaluation of patients with global developmental delay, intellectual disability, and autism spectrum disorder. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 30(2). 2015 Authors

2015 Health Technology Assessment (HTA) Database.

94. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder Full Text available with Trip Pro

Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for children with attention deficit hyperactivity disorder but not well studied in ASD.In a multisite, randomized clinical trial, extended-release guanfacine was compared with placebo in children with ASD accompanied by hyperactivity, impulsiveness

2015 EvidenceUpdates Controlled trial quality: uncertain

95. Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. Full Text available with Trip Pro

Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. The use of genome-wide tests to provide molecular diagnosis for individuals with autism spectrum disorder (ASD) requires more study.To perform chromosomal microarray analysis (CMA) and whole-exome sequencing (WES) in a heterogeneous group of children with ASD to determine the molecular diagnostic yield of these tests in a sample typical of a developmental pediatric

2015 JAMA

96. Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

of telehealth for diagnosis of pediatric patients with suspected Autism Spectrum Disorder? Key Message One randomized controlled trial and three non-randomized studies were identified regarding telehealth diagnosis of Autism Spectrum Disorder in pediatric patients. Tags adolescent, autistic disorder, child, child development disorders, infant, pediatrics, remote consultation, telemedicine, videoconferencing, ehealth, , Pervasive, Remote, Telemonitor, Telepsychiatry Files Rapid Response Summary of Abstracts (...) Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Telehealth for Autism Spectrum Disorder Diagnosis in Pediatric Patients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

97. [Efficacy of early intensive behavioral intervention in autism spectrum disorders]

[Efficacy of early intensive behavioral intervention in autism spectrum disorders] Eficacia de las terapias conductuales tempranas e intensivas en los Trastornos del Espectro Autista [Efficacy of early intensive behavioral intervention in autism spectrum disorders] Eficacia de las terapias conductuales tempranas e intensivas en los Trastornos del Espectro Autista [Efficacy of early intensive behavioral intervention in autism spectrum disorders] Gonzalez L, Pichon-Riviere A, Augustovski F (...) of early intensive behavioral intervention in autism spectrum disorders] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 404. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and issues related to coverage policies for the use of early intensive behavioral interventions in patients with autism spectrum disorder. Authors' conclusions The quality of the evidence found is low. It shows that an EIBI program could

2015 Health Technology Assessment (HTA) Database.

98. Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder

Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder Sun F, Oristaglio J, Levy SE, Hakonarson H, Sullivan N, Fontanarosa J, Schoelles KM Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sun F, Oristaglio J, Levy SE, Hakonarson H, Sullivan N, Fontanarosa J, Schoelles KM. Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technical Brief No. 23. 2015 Authors' objectives This Technical Brief collects and summarizes information on genetic tests clinically available

2015 Health Technology Assessment (HTA) Database.

99. Chelation for autism spectrum disorder (ASD). (Abstract)

Chelation for autism spectrum disorder (ASD). It has been suggested that the severity of autism spectrum disorder (ASD) symptoms is positively correlated with the level of circulating or stored toxic metals, and that excretion of these heavy metals, brought about by the use of pharmaceutical chelating agents, results in improved symptoms.To assess the potential benefits and adverse effects of pharmaceutical chelating agents (referred to as chelation therapy throughout this review) for autism (...) symptoms.This review included data from only one study, which had methodological limitations. As such, no clinical trial evidence was found to suggest that pharmaceutical chelation is an effective intervention for ASD. Given prior reports of serious adverse events, such as hypocalcaemia, renal impairment and reported death, the risks of using chelation for ASD currently outweigh proven benefits. Before further trials are conducted, evidence that supports a causal link between heavy metals and autism

2015 Cochrane

100. Chelation for autism spectrum disorder (ASD). Full Text available with Trip Pro

Chelation for autism spectrum disorder (ASD). It has been suggested that the severity of autism spectrum disorder (ASD) symptoms is positively correlated with the level of circulating or stored toxic metals, and that excretion of these heavy metals, brought about by the use of pharmaceutical chelating agents, results in improved symptoms.To assess the potential benefits and adverse effects of pharmaceutical chelating agents (referred to as chelation therapy throughout this review) for autism (...) symptoms.This review included data from only one study, which had methodological limitations. As such, no clinical trial evidence was found to suggest that pharmaceutical chelation is an effective intervention for ASD. Given prior reports of serious adverse events, such as hypocalcaemia, renal impairment and reported death, the risks of using chelation for ASD currently outweigh proven benefits. Before further trials are conducted, evidence that supports a causal link between heavy metals and autism

2015 Cochrane